14-day Premium Trial Subscription Sign Up For FreeGet Free

Brainstorm Cell Therapeutics Inc. Stock Forecast NASDAQ:BCLI

$3.33 (-4.31%)

Volume: 676k

Closed: Dec 03, 2021

Hollow Logo Score: -1.443

Brainstorm Cell Therapeutics Inc. Stock Forecast

$3.33 (-4.31%)

Volume: 676k

Closed: Dec 03, 2021

Score Hollow Logo -1.443
Which way will BCLI go? Request
Key Stats
Beta 1.14
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 58 and the stock is currently not being overbought or oversold

Volatile ride for Brainstorm Cell Therapeutics Inc. stock price on Friday moving between $3.10 and $3.53
(Updated on Dec 03, 2021)


Sell candidate since 2021-12-03

The Brainstorm Cell Therapeutics Inc. stock price fell by -4.31% on the last day (Friday, 3rd Dec 2021) from $3.48 to $3.33. and has now fallen 5 days in a row. During the day the stock fluctuated 13.87% from a day low at $3.10 to a day high of $3.53. The price has fallen in 6 of the last 10 days, but is still up by 11.37% over the past 2 weeks. Volume has increased on the last day by 418 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 676 thousand shares were bought and sold for approximately $2.25 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -3.13% during the next 3 months and, with a 90% probability hold a price between $2.71 and $3.68 at the end of this 3-month period.

Signals & Forecast

The Brainstorm Cell Therapeutics Inc. stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $3.62. On a fall, the stock will find some support from the long-term average at approximately $3.14. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Monday, November 29, 2021, and so far it has fallen -12.60%. Further fall is indicated until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss

Brainstorm Cell Therapeutics Inc. finds support from accumulated volume at $3.25 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.43 between high and low, or 13.87%. For the last week, the stock has had a daily average volatility of 12.16%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Brainstorm Cell Therapeutics Inc. stock A Buy?

Brainstorm Cell Therapeutics Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Sell candidate.

Current score: -1.443

Predicted Opening Price for Brainstorm Cell Therapeutics Inc. of Monday, December 6, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 6, 2021 Current price
$3.32 $3.33 (Overvalued)
Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

Maxim Group is very positive about BCLI and gave it a "Hold - Buy" rating on Feb 04, 2021. The price target was set to $12.00.

Volatility and Risk
Daily Average Volatility: 12.16 %
Overall Risk: Very High High Medium Low Very Low
Volatility
12.16 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $3.43
Price: $3.33
Support: $3.25

BCLI Insider Trading Show all Trades

INSIDER POWER

7.020

Last 100 transactions
Buy: 2 302 023 | Sell: 327 936 (Shares)
Date Action Amount Person Type
Dec 30, 2020 Sell 25 000 Shah Preetam Common Stock
Nov 17, 2020 Buy 200 Lindborg Stacy Call Option (right to buy)
Sep 08, 2020 Buy 35 000 Waclawski Anthony Common Stock
Sep 08, 2020 Buy 80 000 Waclawski Anthony Stock Option (Right to Buy)
Jul 26, 2020 Buy 31 185 Lebovits Chaim Common Stock
Show all Insider Trades
INSIDER POWER

7.020

Last 100 transactions
Buy: 2 302 023 | Sell: 327 936 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 3.75 12.61 %
3.59 7.68 %
3.48 4.63 %
Current price: 3.33
Support 3.16 -5.23 %
3.05 -8.28 %
2.89 -13.21 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 3.81 14.41 %
3.53 6.01 %
3.43 3.00 %
Current price 3.33
Support 3.25 -2.40%
3.14 -5.71%
2.97 -10.81%

Click to get the best stock tips daily for free!

About Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cell... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT